MALIGNANT OVARIAN TUMORS DIAGNOSTICS DIFFICULTIES

16031 Background: To evaluate the clinical behavior and results of treatment of gestational trophoblastic disease at INEN between 1980 to 2005. Methods: This is a retrospective analysis of patients with gestational trophoblastic disease, clinical characteristics, results of treatment, toxicity, objective response and survival from January 1980 to December 2005. Descriptive statistics and Kaplan-Meier for survival analysis were performed. Results: Since Jan 1980 to Dec 2005. 595 patients were admitted at INEN; Hydatidiform mole 254 (42.7%) choriocarcinoma 201 (33.8%) invasive mole 41(6.8%). FIGO scoring System, high risk (score >6): 247 (41.5%), low risk (score 1–6): 348 (58.5%). Age ranged from 14 to 54 years, with 255 (44%) cases between 20 to 29 years. The sities of metastasis: lung 67.3%, vaginal 17.9%, brain 8.7%, liver 5.1%. The patients with low risks received treatment with Metotrexate 0.4mg/kg x day x 5 days po, reach disease control with a mean course of 6 (1 - 14), complete remission in 66.1% cases and 97% the overall survival rate to 20 years. Patients with high risk received treatment with: MAC 77 patients, MEC 19 patients, EMACO 48 patients and BEP 14 patients and achieved complete remission in 32.5%, 36.8%, 50% and 25% respectively. On the high risk group we detected two groups according to score > 12 and < 12, with diferent probability of survival at 20 years, for the group with score <12, 80% and the group with score >12, 48%. 98 patients were identified with score >12, and the age of these patients ranged from 15 to 51 years, with a mean age of 36.5 years. The blood B- HCG titers of these patients ranged from 198 to 6710,500. Liver and brain metastasis in 26 cases, number metastasis mayor 8 in 78 cases. Conclusions: Gestational trofhoblastic disease is highly curable. Patients of low risk achieved a 97% overall survival rate to 20 years. There are differences in the overall survival rate between patients of high risk with a score < 12 (80%) and score >12 (48%). This group presented with brain and liver metastasis, and it is important to define the best treatment for this group of patients No significant financial relationships to disclose.

Download Full-text

Genetic and clinical characterization of BRCA-associated Hereditary Breast and Ovarian Cancer in Navarra (Spain)

10.21203/rs.2.13095/v3 ◽

2019 ◽

Author(s):

Ainara Ruiz de Sabando ◽

Edurne Urrutia Lafuente ◽

Fermín García-Amigot ◽

Ángel Alonso Sánchez ◽

Lourdes Morales Garofalo ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Genetic Testing ◽

Survival Rate ◽

Clinical Course ◽

Risk Groups ◽

Molecular Characteristics ◽

Overall Survival Rate ◽

Breast And Ovarian Cancer ◽

Brca Carriers

Abstract Background Genetic testing for BRCA1/2 genes is widely used as a strategy to reduce incidence and morbidity of hereditary breast and ovarian cancer. The purpose of this study is to analyse the demographic and molecular characteristics of BRCA germline mutations in Navarra, Spain, and to investigate the clinical profile of hereditary and sporadic breast cancer (BC) and ovarian cancer (OC) in the Community. Methods The study includes 1246 individuals assessed for BRCA1/2 genetic testing in Navarra, during 2000-2016, and a cohort of BC (n=4384) and OC (n=561) from the population-based Navarra Cancer Registry. Distribution and molecular characteristics of BRCA1/2 mutations, as well as, comparative analysis of the clinical course, pathologic features and overall survival of patients in different risk groups were investigated. Results BRCA mutation detection rate was 16%, with higher proportion (63%) of BRCA2 families. Nineteen per cent of mutations were recurrent, one of which, BRCA2 c.6024dupG, showed high association to OC. BRCA carriers had double risk (95% CI=1.04-4.33) of developing multiple malignancies than low risk families and were diagnosed at a much earlier age (16.6 and 11.7 years difference for BC and OC, respectively) when compared to the general population. For BC, BRCA carriers showed a more advanced histological stage, higher risk of bilateral neoplasms (OR=4.3; 95% CI=1.3-11.4, for BRCA2 carriers) and worse overall survival rate at 5-, 10- and 15- years, than women with sporadic tumors. For OC, over 70% of patients of all risk groups showed advanced stages at diagnosis, with the highest 91% among BRCA1 carriers (91%). Furthermore, they also had higher probability of developing bilateral tumors (OR=7.8, 95%CI=1.7-55.7) than the general population. Five-year overall survival rate was worse among women with sporadic OC than in BRCA carriers, but it levelled out over the 15-year period. Conclusions This study describes the molecular features of BRCA1/2 mutations in Navarra and defines the clinical course and outcomes of BRCA associated tumors compared with those of sporadic origin. Long term assessment of mortality and survival will be required to evaluate the impact of BRCA genetic testing program on the health of target population in our community.

Download Full-text

Minimal vulvar cancer: a literature review and own observations

Tumors of female reproductive system ◽

10.17650/1994-4098-2018-14-3-64-70 ◽

2018 ◽

Vol 14 (3) ◽

pp. 64-70

Author(s):

A. A. Il’in ◽

A. S. Khadzhimba ◽

S. Ya. Maksimov ◽

I. V. Sobolev ◽

E. A. Vyshinskaya ◽

...

Keyword(s):

Overall Survival ◽

Survival Rate ◽

Tumor Invasion ◽

Vulvar Cancer ◽

Young Patients ◽

Stage Iv ◽

Depth Of Invasion ◽

Minimal Risk ◽

Overall Survival Rate ◽

Morphological Criteria

Organ-sparing surgeries for vulvar cancer (VC) include wide excision of perineal tissues or hemivulvectomy. The advances in the treatment of VC reduce the risk of complications in patients with somatic pathology and preserve reproductive function in young patients with minimal risk of disease recurrence. The development of new approaches to VC therapy based on currently accepted clinical and morphological criteria will help to improve treatment outcomes.Materials and methods.We retrospectively analyzed the data on 252 patients with VC. Of them, 58 participants had stage I VC, 103 had stage II VC, 79 had stage III VC, and 12 had stage IV VC. The majority of patients (n = 152) underwent vulvectomy; 100 patients underwent extended vulvectomy.Results.Tumor size and depth of invasion are independent prognostic factors determining overall patient survival. The overall survival rate in patients with tumors of 1.5 cm or smaller was 91.7 %, whereas in patients with tumors >2 cm the overall survival rate was 62.2 %. Thefive-year survival rate was 53.9 % in individuals with tumor invasion >1 cm and 84.6 % in individuals with tumor invasion <0.5 cm.Conclusion.We have developed the criteria for minimal vulvar cancer: tumors <2 cm, tumor invasion <5 mm, tumors located outside theclitoris, no tumor emboli in the vessels, no multifocal growth.

Download Full-text

EVALUATION OF THE EFFECTIVENESS OF RETINOBLASTOMA THERAPY IN CHILDREN

Ambiance in Life International Scientific Journal in Medicine of Southern Caucasus ◽

10.36962/alisjmsc06012021135 ◽

2021 ◽

Vol 06 (01) ◽

pp. 135-136

Author(s):

Aigul Bazarbayeva, Gulnara Bulabayeva Aigul Bazarbayeva, Gulnara Bulabayeva ◽

Olesya Pankova, Nargiza Kakharova Olesya Pankova, Nargiza Kakharova

Keyword(s):

Overall Survival ◽

Survival Rate ◽

Early Detection ◽

Early Diagnosis ◽

Pediatric Surgery ◽

Overall Survival Rate ◽

Antitumor Therapy ◽

Scientific Center ◽

Results Of Treatment ◽

Therapeutic Protocol

The paper presents the results of treatment of 113 children with retinoblastoma who were treated at the Scientific Center of Pediatrics and Pediatric Surgery under the RBA-2003 program from 2013 to 2020. Verification of the diagnosis of retinoblastoma was carried out according to international criteria. When analyzing the results of the study, the overall survival rate of children with retinoblastoma was 79%. The therapeutic protocol is highly effective, allowing to obtain high rates of overall survival in the vast majority of patients. The effectiveness of treatment in stage I was 97%, in stage II-90%, in stage III-80%. Early detection of RB promotes early initiation of antitumor therapy, the survival rate of which is more than 90% (I degree - 97%, II degree - 90%). Keywords: retinoblastoma in children, early diagnosis, organ-preserving therapy.

Download Full-text

Genetic and clinical characterization of BRCA-associated Hereditary Breast and Ovarian Cancer in Navarra (Spain)

10.21203/rs.2.13095/v1 ◽

2019 ◽

Author(s):

Ainara Ruiz de Sabando ◽

Edurne Urrutia Lafuente ◽

Fermín García-Amigot ◽

Ángel Alonso Sánchez ◽

Lourdes Morales Garofalo ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Genetic Testing ◽

Survival Rate ◽

Clinical Course ◽

Risk Groups ◽

Molecular Characteristics ◽

Overall Survival Rate ◽

Breast And Ovarian Cancer ◽

Brca Carriers

Abstract Background Genetic testing for BRCA1/2 genes is widely used as a strategy to reduce incidence and morbidity of hereditary breast and ovarian cancer. The purpose of this study is to analyse the demographic and molecular characteristics of BRCA germline mutations in Navarra, Spain, and to investigate the clinical profile of hereditary and sporadic breast cancer (BC) and ovarian cancer (OC) in the Community. Methods The study includes 1246 individuals assessed for BRCA1/2 genetic testing in Navarra, during 2000-2016, and a cohort of BC (n=4384) and OC (n=561) from the population-based Navarra Cancer Registry. Distribution and molecular characteristics of BRCA1/2 mutations, as well as, comparative analysis of the clinical course, pathologic features and overall survival of patients in different risk groups were investigated. Results BRCA mutation detection rate was 16%, with higher proportion (63%) of BRCA2 families. Nineteen per cent of mutations were recurrent, one of which, BRCA2 c.6024dupG, showed high association to OC. BRCA carriers had double risk (95% CI=1.04-4.33) of developing multiple malignancies than low risk families and were diagnosed at a much earlier age (16.6 and 11.7 years difference for BC and OC, respectively) when compared to the general population. For BC, BRCA carriers showed a more advanced histological stage, higher risk of bilateral neoplasms (OR=4.3; 95% CI=1.3-11.4, for BRCA2 carriers) and worse overall survival rate at 5-, 10- and 15- years, than women with sporadic tumors. For OC, over 70% of patients of all risk groups showed advanced stages at diagnosis, with the highest 91% among BRCA1 carriers (91%). Furthermore, they also had higher probability of developing bilateral tumors (OR=7.8, 95%CI=1.7-55.7) than the general population. Five-year overall survival rate was worse among women with sporadic OC than in BRCA carriers, but it levelled out over the 15-year period. Conclusions This study describes the molecular features of BRCA1/2 mutations in Navarra and defines the clinical course and outcomes of BRCA associated tumors compared with those of sporadic origin. Long term assessment of mortality and survival will be required to evaluate the impact of BRCA genetic testing program on the health of target population in our community.

Download Full-text

Efficacy and Toxicity of Folfoxiri for Patients with Metastatic Colorectal Cancer

Open Access Macedonian Journal of Medical Sciences ◽

10.3889/oamjms.2019.368 ◽

2019 ◽

Vol 7 (24) ◽

pp. 4244-4249

Author(s):

Trinh Le Huy ◽

My Hanh Bui ◽

Toi Chu Dinh ◽

Hoang Thi Hong Xuyen

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Survival Rate ◽

Metastatic Colorectal Cancer ◽

Cancer Patients ◽

Stage Iv ◽

Progression Free Survival ◽

Overall Survival Rate ◽

Free Survival ◽

Colorectal Cancer Patients

BACKGROUND: In recent times, scientists have found new treatments for colorectal cancer patients. AIM: The study is to evaluate the efficacy and toxicity of triplet combination chemotherapy of 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) for patients with metastatic colorectal cancer in stage IV. METHODS: Uncontrolled clinical trial carried on 39 stage IV colorectal cancer patients. RESULTS: The overall response rate of the treatment was 79.4%. The average progression-free survival was 13.4 ± 9 months. The overall survival rate at 12th month and 24th month were 90% and 76%, respectively. The proportion of granulocytopenia was 48.9%, no grade 3 or 4. Side effect beyond hematology was most seen in hepatic toxicity with 52.5%, mainly at grade 1. Vomiting was 18.3%, all at grade 1. Other adverse event was very low at percentage. CONCLUSIONS: The triplet combination FOLFOXIRI chemotherapy improves the outcome of patients with metastatic colorectal cancer regarding rate of response, overall survival rate and progression-free survival, and the level of toxicity was acceptable.

Download Full-text

Genetic and clinical characterization of BRCA-associated Hereditary Breast and Ovarian Cancer in Navarra (Spain)

10.21203/rs.2.13095/v2 ◽

2019 ◽

Author(s):

Ainara Ruiz de Sabando ◽

Edurne Urrutia Lafuente ◽

Fermín García-Amigot ◽

Ángel Alonso Sánchez ◽

Lourdes Morales Garofalo ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Genetic Testing ◽

Survival Rate ◽

Clinical Course ◽

Risk Groups ◽

Molecular Characteristics ◽

Overall Survival Rate ◽

Breast And Ovarian Cancer ◽

Brca Carriers

Abstract Background Genetic testing for BRCA1/2 genes is widely used as a strategy to reduce incidence and morbidity of hereditary breast and ovarian cancer. The purpose of this study is to analyse the demographic and molecular characteristics of BRCA germline mutations in Navarra, Spain, and to investigate the clinical profile of hereditary and sporadic breast cancer (BC) and ovarian cancer (OC) in the Community. Methods The study includes 1246 individuals assessed for BRCA1/2 genetic testing in Navarra, during 2000-2016, and a cohort of BC (n=4384) and OC (n=561) from the population-based Navarra Cancer Registry. Distribution and molecular characteristics of BRCA1/2 mutations, as well as, comparative analysis of the clinical course, pathologic features and overall survival of patients in different risk groups were investigated. Results BRCA mutation detection rate was 16%, with higher proportion (63%) of BRCA2 families. Nineteen per cent of mutations were recurrent, one of which, BRCA2 c.6024dupG, showed high association to OC. BRCA carriers had double risk (95% CI=1.04-4.33) of developing multiple malignancies than low risk families and were diagnosed at a much earlier age (16.6 and 11.7 years difference for BC and OC, respectively) when compared to the general population. For BC, BRCA carriers showed a more advanced histological stage, higher risk of bilateral neoplasms (OR=4.3; 95% CI=1.3-11.4, for BRCA2 carriers) and worse overall survival rate at 5-, 10- and 15- years, than women with sporadic tumors. For OC, over 70% of patients of all risk groups showed advanced stages at diagnosis, with the highest 91% among BRCA1 carriers (91%). Furthermore, they also had higher probability of developing bilateral tumors (OR=7.8, 95%CI=1.7-55.7) than the general population. Five-year overall survival rate was worse among women with sporadic OC than in BRCA carriers, but it levelled out over the 15-year period. Conclusions This study describes the molecular features of BRCA1/2 mutations in Navarra and defines the clinical course and outcomes of BRCA associated tumors compared with those of sporadic origin. Long term assessment of mortality and survival will be required to evaluate the impact of BRCA genetic testing program on the health of target population in our community.

Download Full-text

Development and Validation of Nomograms to Predict Lung Metastases in Patients with Ovarian Cancer: A Large Cohort Study

10.21203/rs.3.rs-46013/v1 ◽

2020 ◽

Author(s):

Yufei Yuan ◽

Fanfan Guo ◽

Ruoran Wang ◽

Yidan Zhang ◽

GuiQin Bai

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Survival Rate ◽

Cancer Patients ◽

Lung Metastasis ◽

Cox Regression ◽

Validation Cohort ◽

Lung Metastases ◽

Overall Survival Rate ◽

Newly Diagnosed

Abstract Background Lung metastasis, an independent risk factor affecting the prognosis of patients with ovarian cancer, is associated with poor survival. We tried to develop and validate a nomogram to predict the risk of lung metastases in newly diagnosed patients with ovarian cancer.Methods Patients diagnosed with ovarian cancer from the surveillance, epidemiology and final results (SEER) database between 2010 and 2015 were retrospectively collected. The model nomogram was built based on logistic regression. The consistency index (C-index) was used to evaluate the discernment of the lung metastasis nomogram. Calibration plots was drawn to analyze the consistency between the observed probability and predicted probability of lung metastases in patients with ovarian cancer. The Kaplan-Meier method was used to estimate the overall survival rate, and the influencing factors were included in the multivariate Cox regression (P<0.05) to analyze the independent prognostic factors of lung metastases.Results A total of 16,059 eligible patients were randomly divided into training (n = 11242) and validation cohort (n = 4817). AJCC T, N stage, bone metastases, brain metastases and liver metastases were evaluated as predictors of lung metastases. Finally, a nomogram was constructed. The nomogram based on independent predictors was well calibrated and showed good discriminative ability. The C index is 0.761 (0.736-0.787) for the training cohort and 0.757（0.718-0.795）for the validation cohort. The overall survival rate of ovarian cancer patients with lung metastases was reduced. Mixed histological types, chemotherapy and primary site surgery were factors that affect the overall survival of ovarian cancer patients with lung metastases.Conclusion: The clinical prediction model had high accuracy and can be used to predict the lung metastasis risk of newly diagnosed patients with ovarian cancer, which can guide the treatment of patients with lung metastases.

Download Full-text

Circular RNA S-7 promotes ovarian cancer EMT via sponging miR-641 to up-regulate ZEB1 and MDM2

Bioscience Reports ◽

10.1042/bsr20200825 ◽

2020 ◽

Vol 40 (7) ◽

Author(s):

Fenghua Zhang ◽

Yun Xu ◽

Wenfeng Ye ◽

Jingting Jiang ◽

Changping Wu

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Lymph Node ◽

Survival Rate ◽

Cell Growth ◽

Lymph Node Metastasis ◽

Pearson Correlation ◽

Gynecologic Cancer ◽

Overall Survival Rate ◽

Node Metastasis

Abstract Background: Ovarian cancer (OC) is one lethal gynecologic cancer, with a 5-year survival rate approximately 47% and localized stage diagnosis of 15%. Circular RNAs are promising biomarkers for malignancies. Methods: CiRS-7 expression was confirmed in 40 paired OC and normal adjacent tissues from 40 OC patients with different TNM stages, lymph node metastasis status and overall survival rate, also 5 different OC cell lines by qRT-PCR. Effects of ciRS-7 silence on OC cell phenotypes were determined in OC cells and Xenograft mouse model. StarBase was used to predict binding sites between ciRS-7 and micRNAs. Pearson correlation analysis and RNA-immunoprecipitation assay were used to determine the association between genes. Point mutation and rescue experiments were applied for molecular mechanism investigation. Results: CiRS-7 expression was significantly higher in OC cells and tissues, which was significantly associated with the TNM stages, lymph node metastasis status and overall survival rate in OC patients. CiRS-7 silence inhibited OC cell growth and metastasis. CiRS-7 sponged miR-641 to up-regulate ZEB1 and MDM2 expression in OC development. Conclusion: CiRS-7 serves as a competing endogenous RNA of miR-641 that promoted cell growth and metastasis in OC, via regulating ZEB1 and MDM2-mediated EMT. High ciRS-7 expression was a poor prognosis of TNM stages, lymph node metastasis status and overall survival rate in OC patients. Targeting ciRS-7/miR-641/ZEB1 or ciRS-7/miR-641/MDM2 axis may be a novel diagnostic, prognostic and therapeutic strategy for OC.

Download Full-text

Carbon Ion Radiotherapy for Oligo-Recurrence in the Lung

Pulmonary Medicine ◽

10.1155/2013/219746 ◽

2013 ◽

Vol 2013 ◽

pp. 1-6 ◽

Cited By ~ 5

Author(s):

Naoyoshi Yamamoto ◽

Mio Nakajima ◽

Hirohiko Tsujii ◽

Tadashi Kamada

Keyword(s):

Colorectal Cancer ◽

Lung Cancer ◽

Overall Survival ◽

Survival Rate ◽

Local Control ◽

Local Control Rate ◽

Carbon Ion Radiotherapy ◽

Overall Survival Rate ◽

Carbon Ion ◽

Metastatic Lung

The clinical results after carbon ion radiotherapy for the metastatic lung tumors believed to be in the state of oligo-recurrence were evaluated. One hundred and sixteen lesions in 91 patients with lung cancer metastasis were treated with carbon ion radiotherapy at our institute from April 1997 to February 2011. Regarding the prescribed dose, total dose ranged between 40 gray equivalents (GyE) and 80 GyE, and fraction size ranged from 1 to 16 fractions. After a median followup period of 2.3 years (range, 0.3–13.1 years), the statistical overall survival rate and local control rate were 71.2% and 91.9% at 2 years after treatment, respectively. Treatment-related side effects were not a clinical problem. When classified by the primary organ, there were 49 cases of lung cancer, 20 cases of colorectal cancer, and 22 cases of others. The overall survival rate and local control rate for lung metastasis cases from lung cancer at 2 years after treatment were 81.5% and 92.4%, respectively, and 65.0% and 92.0% regarding lung metastasis from colorectal cancer. Carbon ion beam therapy for the metastatic lung tumors is a safe therapy, and the therapeutic effect is comparable to the outcome obtained from reported surgical resections.

Download Full-text